Drug to treat Alzheimer’s fails to clear clinical trials
Solanezumab, a drug anticipated to potentially aid patients suffering from Alzheimer’s has failed clinical trials, pharma major Eli Lilly on Saturday. A release stated that it did not meet the primary endpoint in the phase three clinical trials of people with mild dementia due to Alzheimer’s disease (AD). Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo....